Press Releases Teva Pharmaceutical Industries Limited OTC Markets

Equities

TEVJF

IL0006290147

Market Closed - OTC Markets Other stock markets 09:30:01 2024-07-12 am EDT			5-day change	1st Jan Change
17.19 ^USD	-0.02%		+16.94%	+99.42%

Jul. 01	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
Jul. 01	Sector Update: Health Care Stocks Slipping in Afternoon Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024	Jul. 02	BU
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses	Jun. 28	BU
Teva Announces Launch of Authorized Generic of Victoza, in the United States	Jun. 25	AQ
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020	Jun. 25	BU
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States	Jun. 24	BU
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	Jun. 04	BU
Teva Pharmaceuticals - New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY Extended-Release Injectable Suspension from Invega Sustenna	Jun. 03	AQ
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)	Jun. 01	BU
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024	Jun. 01	BU
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)	May. 29	BU
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.	May. 22	AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	May. 20	BU
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	May. 20	AQ
New EVP, Teva Global Operations appointed	May. 16	AQ
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations	May. 15	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	May. 09	AQ
Teva Pharmaceutical Industries : Immediate Report	May. 08	PU
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook	May. 08	BU
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	May. 03	AQ
Teva to Present at the 2024 Bank of America Healthcare Conference	May. 02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT